Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pegpleranib

- PMLiVE

Novartis builds its case for novel MS treatment ofatumumab

Detailed results from phase 3 studies published in NEJM

Roche Basel Switzerland

Roche’s Tecentriq combo scores FDA approval for melanoma

Drug approved for patients with BRAF protein mutations

- PMLiVE

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

Milestone payments could reach up to $2bn

- PMLiVE

Roche’s Actemra fails in late-stage severe COVID-19 study

Anti-inflammatory drug unable to improve clinical status of hospitalised patients

- PMLiVE

Biogen plans Spinraza study in SMA patients treated with Novartis’ Zolgensma

Company aims to extend market reach

Roche Basel Switzerland

Roche cites COVID-19 and biosimilars in Q2 decline

Pharmaceutical sales took a 4% hit in Swiss francs

- PMLiVE

Novartis stumbles in Q2 as COVID-19 impacts sales

Net profit drops by 4% as pandemic hits sales

- PMLiVE

Merck, Bayer get FDA priority review for heart failure drug

Target action date set for January 2021

- PMLiVE

Novartis reveals plans for a zero-profit COVID-19 drugs portfolio

Includes 15 medicines from company's generics division

- PMLiVE

Roche pays $775m upfront to access Blueprint’s RET programme

Expands on initial deal that is worth up to $1bn

- PMLiVE

Tecentriq misses the mark in advanced ovarian cancer

PD-L1 inhibitor failed to improved progression-free survival

Roche Basel Switzerland

New data reinforces safety profile of Roche’s Hemlibra

Blockbuster haemophilia A treatment presents a strong challenge to rival drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links